amplification with a normal CDH11 copy number (Figure 2) . MYCN amplification may account for the aggressiveness of the ovarian tumor, as it does for highly fatal neuroblastomas. 7 The evidence indicates that the ovarian tumor was an independent retinoblastoma rather than a metastasis. While our analysis did not attempt to reveal the cell of origin that underwent malignant transformation, marker analysis revealed that it was not of ovarian origin. Instead, we speculate that it may have been a retinal cell displaced into the ovary by an unknown mechanism. Alternatively, a primitive pluripotent cell persisting in the ovary may have acquired the second RB1 and subsequent other mutations allowing the malignant transformation.
1 Two main categories of paraneoplastic retinopathies have been described, including cancer-associated retinopathy and melanomaassociated retinopathy.
2 Cancer-associated retinopathy is found most often in patients with small cell lung carcinoma and affects both rod and cone function, while melanoma-associated retinopathy occurs with metastatic cutaneous or uveal melanoma and affects primarily rod function.
1 Autoantibodies against recoverin and bipolar cells are typically found in cancer-associated retinopathy and melanoma-associated retinopathy, respectively, although other retinal antigens have also been described.
1,3 Herein, we illustrate a case of a more recently recognized paraneoplastic retinopathy, termed acute exudative polymorphous paraneoplastic vitelliform maculopathy (AEPPVM).
Report of a Case.
A 69-year-old woman noted gradually progressive blurred vision in both eyes over 2 years. Three months previously, she experienced subjective loss of peripheral vision bilaterally. Other symptoms included mild decreased night vision and photopsia. Stage I breast cancer was diagnosed 5 years prior and treated with excisional biopsy and radiotherapy. She had a second cancer, stage IV lung cancer with liver metastasis, that was diagnosed 2 years prior and was treated with chemotherapy.
On examination, best-corrected visual acuity was 20/80 OD and 20/70 OS. The anterior segment, optic disc, and retinal vessels were unremarkable bilaterally. Comment. This case illustrates an unusual cause of vision loss in a patient with systemic cancer, namely AEPPVM. This condition manifests with multiple vitelliform lesions and is considered an atypical subset of cancerassociated retinopathy or melanoma-associated retinopathy or a separate paraneoplastic entity. Several authors have associated this entity with underlying cutaneous and choroidal melanoma, but not carcinoma.
3-6 Previous reports have labeled this condition as Vogt-Koyanagi-Haradalike syndrome, melanoma-associated retinopathy syndrome variant, vitelliform maculopathy with skin melanoma, vitelliform paraneoplastic retinopathy associated with melanoma, and AEPPVM.
3-6 While most previously reported cases have occurred in patients with skin or eye melanoma, we are unaware of reports of this condition with carcinoma, as in our case.
Clinicians should be aware of AEPPVM. Differentiation from choroidal metastasis can be made by clinical examination and more specifically by optical coherence tomography in that the choroid is flat in AEPPVM, whereas it is elevated with choroidal metastases. In our case, optical coherence tomography showed elevated retina and flat choroid, consistent with AEPPVM. Superficially, the optical coherence tomography changes resembled pigment epithelial detachment, but close scrutiny disclosed flat retinal pigment epithelium and subretinal fluid with dense debris.
Symptoms from paraneoplastic retinopathy can occur before or after the discovery of the primary malignant neoplasm.
1,2 Systemic evaluation for primary cancer, particularly cutaneous or uveal melanoma, is indicated. In our case, systemic evaluation showed no sign of melanoma, and the previously diagnosed carcinomas were confirmed. There is a remote possibility that our patient could have had a regressed cutaneous melanoma or undetected visceral melanoma.
In summary, we describe an unusual paraneoplastic syndrome, namely AEPPVM. This condition should be recognized by clinicians, and systemic evaluation for the primary malignant neoplasm should be performed owing to the high association with cutaneous and choroidal melanoma and, now, carcinoma. 
Early Diabetes Mellitus or Hypertension Is Not Significantly Associated With Severity of Vision Loss in Nonarteritic Anterior Ischemic Optic Neuropathy
G laucoma is a progressive optic neuropathy with features similar to nonarteritic anterior ischemic optic neuropathy (NAION), the most common optic neuropathy causing acute vision loss. Glaucoma has an annual incidence rate of 240 per capita, while NAION has an annual incidence of 2.3 per capita among individuals older than 50 years.
1,2 Early diabetes mellitus (DM)-defined as an absence of clinically visible diabetic retinopathy-may be associated with upregulation and downregulation of intraocular interferon, interleukins, and other cytokines promoting neuroprotection. 3 The initial Ocular Hypertension Treatment Study report documented a protective effect of early DM in glaucoma development, but reanalysis showed no effect.
4,5
Studies have shown DM to be a risk factor for NAION, but it is possible that early DM could have neuroprotective effects in NAION. Hayreh and Zimmerman 6 had documented less severe visual field loss for diabetic patients with NAION. However, 11% of their participants had juvenile diabetes, 36% had diabetic retinopathy, and the investigators had used manual kinetic perimetry. To discern the role of early DM in NAION, we have studied patients aged 50 years or older without diabetic retinopathy using automated static perimetry.
Methods.
We reviewed the records of all patients with NAION evaluated by the neuro-ophthalmology service between October 1990 and August 2009, after obtaining institutional review board approval. Criteria for NAION were similar to those used in past studies. 
